Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight

The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia

Regulation of glucagon secretion by incretins

Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Response to Fritsche et al. (GINGER study)

Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes